AstraZeneca expands 1st-line lung cancer Immuno-Oncology programme opportunities

AstraZeneca has provided an update on its Immuno-Oncology (IO) late-stage clinical development programme in 1st-line non-small cell lung cancer (NSCLC), including a refinement of the Phase III MYSTIC trial. The MYSTIC trial was initially designed to assess the benefit of durvalumab monotherapy and durvalumab and tremelimumab (durva + treme) combination therapy versus http://www.worldpharmanews.com/astrazeneca/3776-astrazeneca-expands-1st-line-lung-cancer-immuno-oncology-programme-opportunities